IBB – XLV Biotech Sector Post JP-Morgan Conference

  iShares Nasdaq Biotechnology (IBB) – Nasdaq Health Care Select Sector SPDR ETF (XLV)–NYSE   The best indicators for our biotech portfolios are the biotechnology indices IBB, NBI, XBI or XLV..

BMY – A Bull Flag Breakout or A Head Fake

  Bristol-Myers Squibb Company (BMY)  -NYSE Interesting price action since October 15th, after touching the support line $47.52 and bouncing back to start a new uptrend, we were looking to reach.

Caution, SPY – Forming A Rare Tri-Star Pattern

  SPDR S&P 500 ETF (SPY) –NYSE The SPY had an extreme price action during the last two months after reaching the All-Time-High 201.90 points on September 19th, followed by a.

MRK – A Falling Knife Or a Golden Opportunity

  Merck & Co. Inc. (MRK) -NYSE Many speculation going around the huge drop in MRK’s share price in just one week, dropping from the $60.18 (closing on 10/08) to reach.

CNAT – A Quick Chart Update

  Conatus Pharmaceuticals Inc. (CNAT) –Nasdaq CNAT was trading within a downtrend channel since June 16th after reaching the high of $9.90, finding a base around the $6.00 weekly support line.

SRPT- A Squeeze In The Making

  Sarepta Therapeutics, Inc. (SRPT)-Nasdaq   Sarepta is preparing for a busy 4th quarter ahead of the NDA submission as confirmed again by the company’s CEO Chris Garabedian during the Morgan.

Merck – Preparing For The Next Move

  Merck & Co. Inc. (MRK) -NYSE   Lately, Merck was under the spot light after Idenix Pharmaceuticals deal, paying $3.85 Billion more than triple Idenix’s market capitalization before the deal.

SPY – A Quick Look at The Broader Market

SPDR S&P 500 (SPY) –NYSE   Yesterday we got a sharp turn in the SP-500 as the daily chart of the SPY (S&P 500 ETF) drops sharply and breaks down the.

Tekmira – Is It The Bottom Yet

  Tekmira Pharmaceuticals Corp (TKMR) –Nasdaq   Tekmira is the new “fallen star” after the wild run started Jan 07th, 2014 from $7.66, and reaching the all time high $31.48 mid.

BMY – In The Inflection Point

  Bristol-Myers Squibb Company (BMY) –NYSE   Bristol-Myers Squibb Co. (BMY) had a wild year, up from the lows of $41.11 in late August 2013 to reach a new 12 years.

RTRX – In a Consolidation Mode

Retrophin, Inc. (RTRX) –Nasdaq   During the last 13 trading days, RTRX trading along the 200-Day moving avarage (red line) with small candlestick (doji) on a descending volume confirming the consolidation.

IBB – In the Decision Zone

iShares Nasdaq Biotechnology (IBB) – Nasdaq The best indicators for our biotech portfolios are the biotechnology indices IBB, NBI, XBI or XLV. We will maintain our focus on the IBB as.

Progenics: Consolidation Ahead of the AdCom

Progenics Pharmaceuticals, Inc. (PGNX) -Nasdaq   Relistor has been approved by regulatory authorities in the U.S., countries in the E.U., Canada and Australia since 2008 for treatment of OIC in advanced-illness.

IBB – Biotech Sector in The Despondency Point

iShares Nasdaq Biotechnology (IBB) – Nasdaq The best indicators for our biotech portfolios are the biotechnology indices IBB, NBI, XBI or XLV. We will maintain our focus on the IBB as.

Pfizer – Technical points to watch

Pfizer Inc. (PFE) -NYSE A long awaited date from Pfizer revealed on Sunday April 04, 2014 at the AACR-2014. Pfizer  announced detailed results from the PALOMA-1 study, a randomized Phase 2 study.

IBB – In The Decision Zone

iShares Nasdaq Biotechnology (IBB) -Nasdaq The best indicator for our biotech portfolios are biotechnology indices such as IBB, NBI, XBI or XLV. By looking at the IBB daily chart, we get the.

BMY – Quick Chart Update

Bristol-Myers Squibb Company (BMY)  -NYSE   Interesting price action since September 9th after breaking out the downtrend line around $41.90, we kept watching the chart day after day during the preparation.

ONTX – Looking For The Reversal Pattern

Onconova Therapeutics, Inc. (ONTX) -Nasdaq   Onconova has recently plunged about $19 from the 52-week high at $31.13, reached just a month ago to the current level in mid-$13s and reaching the.

Merck – Quick Chart Review

Merck & Co. Inc. (MRK) -NYSE For the first time since March 1st, MRK’s price dropped below its 200-Day Moving Average. This is worth a deeper look at the price action.

ACHN – In Consolidation Mode

Achillion Pharmaceuticals, Inc. (ACHN – Nasdaq) On  July 1, 2013 the FDA placed a clinical hold on Achillion’s hep C drug and the shares plunged 22% from $8.36 to $6.17 the.

Browsing 20 / articles